CanniMed Therapeutics IncTSX: CMED

CanniMed Therapeutics Inc. Opens the Market

· Issued by CanniMed Therapeutics Inc via CNW

TORONTO, Dec. 29, 2016 /CNW/ - Brent Zettl, President and CEO, CanniMed Therapeutics Inc. (TSX:CMED) joined Brady Fletcher, Managing Director, TSX Venture Exchange to open the market. CanniMed is a Canadian-based, international plant biopharmaceutical company with 15 years of pharmaceutical cannabis cultivation experience. The Company has a plant biotechnology research and product development program focused on the production of plant-based materials for pharmaceutical, agricultural and environmental applications. CanniMedTherapeutics Inc., will commence trading on Toronto Stock Exchange on December 29, 2016.

SOURCE TMX Group Limited

www.cannimed.caCopyright CNW Group 2016

View original source (CNW)CanniMed Therapeutics Inc on 6ix

Later from CanniMed Therapeutics

All CanniMed Therapeutics news releases